A roadmap for driving CAR T cells toward the oncogenic immunopeptidome

Area of Science:

• Oncology
• Immunotherapy
• Genomics

Background:

• CAR T-cell therapy is a promising cancer treatment but is limited by the lack of antigens exclusively and stably expressed in tumors.
• Identifying suitable targets is crucial for effective and safe CAR T-cell therapy.

Purpose of the Study:

• To provide proof of principle for the development of peptide-centric (PC)-CARs.
• To evaluate the efficacy of PC-CARs targeting the oncogenic immunopeptidome of neuroblastoma in pre-clinical models.

Main Methods:

• Comprehensive multi-omics analysis to identify neuroblastoma-specific antigens.
• Development and pre-clinical testing of novel peptide-centric (PC)-CAR T-cells.

Main Results:

• Demonstrated the feasibility of targeting the oncogenic immunopeptidome of neuroblastoma.
• Provided pre-clinical evidence for the efficacy of PC-CARs in neuroblastoma models.

Conclusions:

• PC-CARs represent a novel strategy to overcome target antigen limitations in CAR T-cell therapy.
• This approach shows promise for developing effective treatments for neuroblastoma.